Healthy aging is a theme that concerns many people. Not only because of physical changes, but also because the brain and mental resilience change along with the years. In this quest, concepts such as neuroplasticity, longevity, and even psychedelics like psilocybin are appearing with increasing frequency. At the same time, there is growing attention to nutrients from mushrooms, including ergothioneine, a substance often described in research as a stable cellular protector.
In this article, we explore the theory behind psilocybin, ergothioneine, and brain plasticity in relation to therapy and healthy aging. In doing so, we make a clear distinction between what has been found in the laboratory, what is being investigated in small human studies, and what people sometimes describe as experience. This is not medical advice, and no guarantees can be given regarding effects or safety.
Aging as an interplay of systems
Biologically speaking, aging is not a single “switch” that slowly turns down. Rather, it is a network of processes that influence one another. In science, attention is often focused on, among other things, DNA damage, changes in energy metabolism (mitochondria), the accumulation of senescent cells (cells that no longer function properly but can still release inflammatory substances), and an increase in chronic low-grade inflammation.
The brain changes as well. Some networks become less flexible, which can make it more difficult to break ingrained thought patterns, regulate stress, or learn new coping skills. It is precisely at this intersection that the subject of therapy comes into play: how do you remain mentally agile, how do you process stress or trauma, and how do you support changes in behavior and meaning-making as you get older?
Psilocybin and therapy: what is and is not known
Psilocybin is a substance that is converted into psilocin in the body. In research, psilocybin is primarily known for its effects on consciousness, emotional processing, and brain networks. In therapeutic contexts, there is often talk of the possibility of temporarily experiencing greater mental flexibility, which can help in exploring patterns, feelings, and beliefs.
It is important to distinguish between different types of evidence. There are studies that examine psychological outcomes in humans, but there is also fundamental research that focuses on cells or animal models. Results from cell studies can be interesting as a hypothesis, but they do not automatically mean that “rejuvenation” occurs in humans or that there is a proven effect on longevity.
What does consistently recur in the literature surrounding psychedelics is the importance of context. When people use psilocybin with therapeutic guidance, it usually involves a process of preparation, a session, and subsequent integration. It is in that integration that “therapy” becomes visible: translating experiences into sustainable behavioral change, better emotion regulation, or a different relationship with stress.
Brain plasticity: why flexibility is relevant as you age
Neuroplasticity refers to the brain's ability to adapt connections based on experience. That ability does not simply decline linearly, but it can change. Factors such as sleep, exercise, stress levels, social connection, and mental challenge play a role in this.
Research into psychedelics often examines mechanisms associated with plasticity, including changes in network dynamics and processes involved in learning. The hypothesis is that some people can temporarily step out of rigid patterns, potentially making psychotherapy feel more effective. At the same time, it remains uncertain how strong and long-lasting this effect is, and in whom it does or does not occur.
For a therapeutic approach, this is important: “plasticity” without direction can also be overwhelming. Therefore, many modern models emphasize the importance of careful guidance, clear intentions, a safe setting, and aftercare. This applies especially to people with vulnerabilities, complex stress, or previous dysregulation.
Ergothioneine: a mushroom compound with an interesting hypothesis
Ergothioneine is a substance that occurs relatively frequently in some mushrooms. In scientific publications, ergothioneine is often described as an antioxidant-like compound that the body can actively absorb via specific transport mechanisms. That detail makes it interesting for researchers: it suggests that the body does not treat ergothioneine as a “random substance,” but possibly as functionally relevant.
However, the step from “biochemically interesting” to “noticeable effect in humans” is a large one. Here, too, part of the evidence is indirect, for example through associations between lower levels and health outcomes, or through animal studies. In human studies, the size is often limited and the duration relatively short, making it too early to draw firm conclusions about healthy aging.
What you can take away from it, however, is a broader perspective: healthy aging rarely revolves around a single substance. It is more about system support, such as energy metabolism, inflammation balance, recovery, sleep quality, and mental resilience.
Synergy as an idea, not a proven protocol
In some articles and discussions, the combination of psilocybin and ergothioneine is outlined as a kind of “mental plus physical” model: psilocybin is thought to primarily support mental flexibility and emotional processing, while ergothioneine is theoretically focused more on cellular protection and oxidative stress. Other substances are sometimes added to this within the broader longevity framework, such as agents linked in research to the clearing of senescent cells or the influencing of inflammatory processes.
It is important to continue viewing this as hypothesis formation. “Synergy” sounds appealing, but combinations can also have unexpected effects and are rarely well-studied as a whole. Moreover, therapeutic relevance varies from person to person. While one person benefits most from lifestyle interventions and psychotherapy, another seeks deeper understanding through altered states. The question, then, should not only be “does it work?”, but also “does it suit my situation and capacity?”
Safety, context and harm reduction
With psychedelics, safety is not a secondary concern. Effects can be intense and can expose vulnerabilities. Interactions with medication or underlying mental health issues can also increase risks. Therefore, it is wise to always approach psychedelic topics from a harm reduction perspective: good preparation, realistic expectations, attention to the set and setting, and a plan for integration and aftercare.
From a practical and factual perspective, it is also important to note that sessions with MDMA can currently only be discussed within scientific research or in clinical practice through harm reduction. This means that information often focuses on risk reduction and context, not on making medical claims or promising outcomes.
Those primarily interested in psilocybin from a therapeutic perspective can delve into how psilocybin therapy is typically structured, which themes frequently recur in integration, and what questions to ask a therapist. You can find a background article on this topic on the page about psilocybin therapy.
What can you take away when thinking about “healthy aging”?
If you look through the hype, a few down-to-earth points remain:
First: mental health and aging influence each other. Chronic stress, poor sleep, and social isolation can exacerbate both mental health issues and physical decline.
Secondly: therapy can play a key role in how you age, because it helps with emotion regulation, finding meaning, grief, relationship patterns, and breaking avoidance.
Thirdly: substances such as psilocybin are being researched, but are not a simple “anti-aging” solution. If they mean anything at all, it is likely as part of a broader process involving guidance and integration, rather than as a standalone intervention.
If you are considering a guided program and would like to discuss what is possible within a harm reduction framework, you can sign up for an intake via sign up for MDMA session. Such a registration is not a promise of treatment, but a starting point to carefully explore questions, safety, and suitable options.
Conclusion
Psilocybin, ergothioneine, and brain plasticity together form an interesting conversation about healthy aging: a combination of mental flexibility, cellular hypotheses, and the role of therapy in sustainable change. Science is constantly evolving, and many conclusions are provisional, certainly regarding aging and long-term effects. A realistic, safe approach therefore requires nuance, proper guidance, and attention to integration, with harm reduction as the foundation.
Source for further information: Staying young with psilocybin and ergothioneine.
English 
Dutch 
German 
French